Geron Reports Q1 Revenue Growth of $61.8M and Reiterates Full-Year Guidance
Geron Corporation (NASDAQ:GERN) reported first-quarter 2026 net revenue of $61.8 million, a 31% year-over-year increase driven by the continued commercialization of Rytelo in the U.S. The company reiterated its full-year guidance for Rytelo revenue between $220–$240 million and outlined progress on European expansion plans.
Topics: pharma pipeline_update revenue_growth